This inventor holds 1 USPTO granted patent. Top assignee: Kyowa Hakko Kirin Co., Limited. Active years: 2009.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2009
Title: The Innovations of Takafumi Tomura: A Pioneer in Cancer Treatment
Introduction
Takafumi Tomura, a distinguished inventor based in Takasaki, Japan, has made significant contributions to the field of cancer treatment with his innovative work on antibodies. His research focuses on developing therapeutic options for malignant tumors, especially those that have been historically challenging to treat.
Latest Patents
Takafumi Tomura holds a notable patent for the Anti-A33 antibody, which represents a breakthrough in targeting A33-expressing tumor cells. This invention details an antibody or an antibody fragment that utilizes the immune system's mechanisms, specifically ADCC (antibody-dependent cell-mediated cytotoxicity) and CDC (complement-dependent cytotoxicity), without yielding HAHA (human anti-human antibodies). The patent offers a preventive or therapeutic agent that could significantly aid in combating various solid tumors, showcasing Tomura's commitment to advancing cancer therapeutics.
Career Highlights
Currently, Takafumi Tomura is affiliated with Kyowa Hakko Kirin Co., Limited, where he continues to push the boundaries of medical science. His dedication to research in antibody development exemplifies his role as an innovator in the pharmaceutical industry. The potential applications of his work could usher in a new era of personalized cancer treatment.
Collaborations
Throughout his career, Tomura has collaborated with esteemed professionals such as Shiro Kataoka and Noriko Otani. These partnerships have enabled him to integrate diverse insights and expertise into his research, further enhancing the effectiveness and reach of his innovations.
Conclusion
Takafumi Tomura's contributions to the field of medicine, particularly through his patent for the Anti-A33 antibody, underline his status as an influential inventor. With the potential to improve treatment outcomes for difficult-to-treat tumors, his work continues to inspire advancements in cancer therapeutics, aiming for a brighter future for patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile